LAVIPHARM S.A. NA EO 1
Research LAVIPHARM S.A. NA EO 1 (BXA0) on Bullrun: market cap EUR 249.68M, P/E 48.7, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBXA0
- ExchangeF
- CountryGreece
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 249.68M
- P/E48.7
- Dividend yield1.3%
- Financial periodFY2025
- RevenueEUR 62.58M
- Revenue growth18.2%
- Net incomeEUR 5.99M
- Free cash flowEUR 2.05M
- Gross margin48.4%
Valuation Snapshot
latest market cap is EUR 249.68M; P/E is 48.7; dividend yield is 1.3%.
Peer valuation comparison
Latest P/E is 48.73x versus a Healthcare sector median of 24.46x (99.2% above).
Latest dividend yield is 1.28% versus a Healthcare sector median of 2.11% (39.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 62.58M | EUR 5.99M | EUR 2.05M | 48.4% | 0.03 | EUR 6.11M | EUR 32.67M | EUR 56.42M |
| FY2024 | EUR 52.95M | EUR 8.98M | -EUR 5.00M | 47.4% | 0.05 | EUR 5.59M | EUR 33.82M | EUR 52.98M |
| FY2023 | EUR 47.84M | EUR 1.87M | -EUR 3.77M | 46.3% | 0.01 | EUR 8.44M | EUR 32.37M | EUR 42.74M |
| FY2022 | EUR 39.06M | EUR 834.00K | -EUR 32.27M | 45.1% | 0.04 | EUR 18.24M | EUR 37.07M | EUR 40.28M |
| FY2021 | EUR 39.72M | EUR 1.72M | EUR 2.19M | 40.0% | 0.1 | EUR 1.64M | EUR 37.22M | -EUR 9.98M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 249.68M | 48.7 | 1.4% | 0.02 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.02 EUR, yield 1.3%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.02 EUR |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LAVIPHARM S.A. NA EO 1's market cap?
LAVIPHARM S.A. NA EO 1's market capitalization is EUR 249.68M.
What is LAVIPHARM S.A. NA EO 1's P/E ratio?
LAVIPHARM S.A. NA EO 1's price-to-earnings (P/E) ratio is 48.7.
Does LAVIPHARM S.A. NA EO 1 pay a dividend?
LAVIPHARM S.A. NA EO 1 has a dividend yield of 1.3%.
What does LAVIPHARM S.A. NA EO 1 do?
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.